JP2018535948A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535948A5 JP2018535948A5 JP2018518592A JP2018518592A JP2018535948A5 JP 2018535948 A5 JP2018535948 A5 JP 2018535948A5 JP 2018518592 A JP2018518592 A JP 2018518592A JP 2018518592 A JP2018518592 A JP 2018518592A JP 2018535948 A5 JP2018535948 A5 JP 2018535948A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- lepr
- antigen
- binding fragment
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000005861 leptin receptors Human genes 0.000 claims description 41
- 108010019813 leptin receptors Proteins 0.000 claims description 41
- 239000000427 antigen Substances 0.000 claims description 40
- 102000036639 antigens Human genes 0.000 claims description 40
- 108091007433 antigens Proteins 0.000 claims description 40
- 239000012634 fragment Substances 0.000 claims description 38
- 150000001413 amino acids Chemical group 0.000 claims description 29
- 102000016267 Leptin Human genes 0.000 claims description 20
- 108010092277 Leptin Proteins 0.000 claims description 20
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 20
- 229940039781 leptin Drugs 0.000 claims description 20
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 19
- 101001129927 Homo sapiens Leptin receptor Proteins 0.000 claims description 19
- 102000007318 human leptin receptor Human genes 0.000 claims description 19
- 230000011664 signaling Effects 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 14
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 208000006132 lipodystrophy Diseases 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 8
- 230000007812 deficiency Effects 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 8
- 230000019491 signal transduction Effects 0.000 claims description 7
- 101001063991 Homo sapiens Leptin Proteins 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 6
- 102000049953 human LEP Human genes 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 102000006501 Angiopoietin-like Proteins Human genes 0.000 claims description 4
- 108010019425 Angiopoietin-like Proteins Proteins 0.000 claims description 4
- 102000051325 Glucagon Human genes 0.000 claims description 4
- 108060003199 Glucagon Proteins 0.000 claims description 4
- 108010063919 Glucagon Receptors Proteins 0.000 claims description 4
- 102100040890 Glucagon receptor Human genes 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 claims description 4
- 101710103228 Sodium/glucose cotransporter 2 Proteins 0.000 claims description 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 4
- 229960001058 bupropion Drugs 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 4
- 229960004666 glucagon Drugs 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000000736 Amenorrhea Diseases 0.000 claims description 2
- 206010001928 Amenorrhoea Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- PWDLDBWXTVILPC-WGAVTJJLSA-N CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 Chemical compound CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 PWDLDBWXTVILPC-WGAVTJJLSA-N 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 201000005948 Donohue syndrome Diseases 0.000 claims description 2
- 208000003929 Familial Partial Lipodystrophy Diseases 0.000 claims description 2
- 206010056465 Food craving Diseases 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 108010001127 Insulin Receptor Proteins 0.000 claims description 2
- 102100036721 Insulin receptor Human genes 0.000 claims description 2
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 2
- 208000013262 Localized lipodystrophy Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 230000003187 abdominal effect Effects 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 208000015228 acquired partial lipodystrophy Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- 231100000540 amenorrhea Toxicity 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 229940012191 bupropion / naltrexone Drugs 0.000 claims description 2
- 102220429788 c.1226C>A Human genes 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 2
- 229960000815 ezetimibe Drugs 0.000 claims description 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 230000002267 hypothalamic effect Effects 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 229960005060 lorcaserin Drugs 0.000 claims description 2
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- 108700008455 metreleptin Proteins 0.000 claims description 2
- 229960000668 metreleptin Drugs 0.000 claims description 2
- 229960003562 phentermine Drugs 0.000 claims description 2
- 229960003611 pramlintide Drugs 0.000 claims description 2
- 108010029667 pramlintide Proteins 0.000 claims description 2
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 claims description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229960004394 topiramate Drugs 0.000 claims description 2
- 229960002911 zonisamide Drugs 0.000 claims description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims description 2
- 240000006409 Acacia auriculiformis Species 0.000 claims 1
- 229940127355 PCSK9 Inhibitors Drugs 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940122392 PCSK9 inhibitor Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000249 far-infrared magnetic resonance spectroscopy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562240021P | 2015-10-12 | 2015-10-12 | |
| US62/240,021 | 2015-10-12 | ||
| US201662359757P | 2016-07-08 | 2016-07-08 | |
| US62/359,757 | 2016-07-08 | ||
| US201662375495P | 2016-08-16 | 2016-08-16 | |
| US62/375,495 | 2016-08-16 | ||
| US201662393143P | 2016-09-12 | 2016-09-12 | |
| US62/393,143 | 2016-09-12 | ||
| PCT/US2016/056465 WO2017066204A1 (en) | 2015-10-12 | 2016-10-11 | Antigen-binding proteins that activate the leptin receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021039405A Division JP7165225B2 (ja) | 2015-10-12 | 2021-03-11 | レプチン受容体を活性化させる抗原結合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535948A JP2018535948A (ja) | 2018-12-06 |
| JP2018535948A5 true JP2018535948A5 (cg-RX-API-DMAC7.html) | 2019-11-21 |
| JP7034068B2 JP7034068B2 (ja) | 2022-03-11 |
Family
ID=57184864
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018518592A Active JP7034068B2 (ja) | 2015-10-12 | 2016-10-11 | レプチン受容体を活性化させる抗原結合タンパク質 |
| JP2021039405A Active JP7165225B2 (ja) | 2015-10-12 | 2021-03-11 | レプチン受容体を活性化させる抗原結合タンパク質 |
| JP2022169008A Active JP7436603B2 (ja) | 2015-10-12 | 2022-10-21 | レプチン受容体を活性化させる抗原結合タンパク質 |
| JP2023202680A Active JP7699191B2 (ja) | 2015-10-12 | 2023-11-30 | レプチン受容体を活性化させる抗原結合タンパク質 |
| JP2024018406A Active JP7759417B2 (ja) | 2015-10-12 | 2024-02-09 | レプチン受容体を活性化させる抗原結合タンパク質 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021039405A Active JP7165225B2 (ja) | 2015-10-12 | 2021-03-11 | レプチン受容体を活性化させる抗原結合タンパク質 |
| JP2022169008A Active JP7436603B2 (ja) | 2015-10-12 | 2022-10-21 | レプチン受容体を活性化させる抗原結合タンパク質 |
| JP2023202680A Active JP7699191B2 (ja) | 2015-10-12 | 2023-11-30 | レプチン受容体を活性化させる抗原結合タンパク質 |
| JP2024018406A Active JP7759417B2 (ja) | 2015-10-12 | 2024-02-09 | レプチン受容体を活性化させる抗原結合タンパク質 |
Country Status (32)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| KR102563568B1 (ko) | 2016-11-08 | 2023-08-04 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체에 길항하는 항원-결합 단백질 |
| CN115025331B (zh) | 2017-05-05 | 2024-06-14 | 里珍纳龙药品有限公司 | 自动注射器和相关使用方法 |
| CA3084385A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
| EP4596043A3 (en) | 2018-04-06 | 2025-10-01 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia |
| WO2020075417A1 (ja) * | 2018-10-11 | 2020-04-16 | 住友化学株式会社 | プロピレンオキサイド精製装置、及び、プロピレンオキサイドの製造方法 |
| CN113424060B (zh) * | 2019-01-31 | 2024-11-26 | 美国西门子医学诊断股份有限公司 | 抗纳洛酮和抗纳曲酮单克隆抗体及其生产和使用方法 |
| US20220288169A1 (en) * | 2019-05-24 | 2022-09-15 | The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College | Compositions and methods for the treatment and prevention of hypoglycemic complications |
| CN114391022B (zh) * | 2019-07-02 | 2023-12-12 | 上海科技大学 | 抗瘦素受体的抗体 |
| KR102863417B1 (ko) | 2019-12-03 | 2025-09-24 | 마이크론 테크놀로지, 인크. | 저장 디바이스를 위한 캐시 아키텍처 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| KR20230069969A (ko) * | 2020-09-15 | 2023-05-19 | 리제너론 파마슈티칼스 인코포레이티드 | 통증에 대한 lepr 아고니스트의 사용 |
| US20240153638A1 (en) | 2021-02-22 | 2024-05-09 | Regeneron Pharmaceuticals, Inc. | Method for diagnosing and treating partial lipodystrophy |
| CN114456124B (zh) * | 2021-12-30 | 2023-04-21 | 华南农业大学 | 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用 |
| WO2024259313A1 (en) | 2023-06-16 | 2024-12-19 | Regeneron Pharamceuticals, Inc. | Medical device packaging and related methods |
| AR134008A1 (es) | 2023-10-02 | 2025-11-26 | Regeneron Pharma | Sistema de seguridad de dispositivo de administración de fármaco |
| JP2025148269A (ja) | 2024-03-15 | 2025-10-07 | イーライ リリー アンド カンパニー | 肥満を治療するための単独又は併用療法としてのレプチン受容体アゴニスト抗体 |
| WO2025227054A1 (en) * | 2024-04-25 | 2025-10-30 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies binding to leptin and uses thereof |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5912123A (en) | 1994-09-14 | 1999-06-15 | Progenitor, Inc. | Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology |
| US5856098A (en) | 1994-09-14 | 1999-01-05 | Progenitor, Inc. | Detection of a leptin receptor variant |
| US6451523B1 (en) | 1994-09-14 | 2002-09-17 | Interneuron Pharmaceuticals, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| US5643748A (en) | 1994-09-14 | 1997-07-01 | Progenitor, Inc. | HU-B1.219, a novel human hematopoietin receptor |
| US6977240B1 (en) * | 1995-11-27 | 2005-12-20 | Millenium Pharmaceuticals, Inc. | Methods of using the OB receptor antibodies to treat bodyweight disorders |
| US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| EP0885299B1 (en) | 1996-01-08 | 2005-10-26 | Genentech, Inc. | Ob receptor and ligands |
| US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| US7063958B1 (en) | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
| AU2476301A (en) | 1996-01-16 | 2001-05-24 | Rockefeller University, The | DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof |
| AU1833197A (en) | 1996-01-18 | 1997-08-11 | Progenitor, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| CA2244693A1 (en) | 1996-01-23 | 1997-07-31 | Progenitor, Inc. | Methods for using the obese gene and its gene product to stimulate hematopoietic development |
| AUPN780096A0 (en) * | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
| US7067472B1 (en) | 1996-06-04 | 2006-06-27 | The Scripps Research Institute | Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies |
| US5965521A (en) | 1997-02-25 | 1999-10-12 | Eli Lilly Company | Pulsatile delivery of leptin receptor ligands |
| IL120733A0 (en) | 1997-04-29 | 1997-08-14 | Yeda Res & Dev | Leptin as an inhibitor of cell proliferation |
| US6696411B1 (en) | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| AU767068B2 (en) | 1999-06-11 | 2003-10-30 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of leptin activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| PT2219031E (pt) | 2001-10-22 | 2013-05-17 | Amgen Inc | Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento |
| IL162269A0 (en) * | 2001-12-05 | 2005-11-20 | Baylor College Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
| FR2852397B1 (fr) | 2003-03-10 | 2005-04-29 | Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal. | |
| DE10353593A1 (de) | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| JPWO2005056602A1 (ja) * | 2003-12-12 | 2008-03-06 | 中外製薬株式会社 | アゴニスト活性を有する改変抗体のスクリーニング方法 |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| US7863240B2 (en) | 2004-10-08 | 2011-01-04 | Enzo Therapeutics, Inc. | Methods and uses of leptin in hepatocellular carcinoma |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| GB0715216D0 (en) | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
| US20100260772A1 (en) | 2007-09-28 | 2010-10-14 | The Trustees Of Columbia University In The City Of New York | Methods for treating or preventing diseases associated with low bone mass |
| CA2742968C (en) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| NO2792236T3 (cg-RX-API-DMAC7.html) | 2009-07-08 | 2018-04-14 | ||
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| PL3095871T3 (pl) | 2010-02-08 | 2019-10-31 | Regeneron Pharma | Mysz zawierająca wspólny łańcuch lekki |
| CN103298937B (zh) | 2010-11-17 | 2016-05-25 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| US20120258073A1 (en) | 2011-02-10 | 2012-10-11 | Christian Gerdes | Immunotherapy |
| ES2946169T3 (es) | 2011-02-25 | 2023-07-13 | Regeneron Pharma | Ratones ADAM6 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| IL273982B2 (en) | 2011-08-05 | 2023-03-01 | Regeneron Pharma | Humanized mice possess a universal light chain |
| GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| AU2013271737A1 (en) | 2012-06-05 | 2015-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for making fully human bispecific antibodies using a common light chain |
| SG10201701831VA (en) | 2012-09-12 | 2017-05-30 | Genzyme Corp | Fc containing polypeptides with altered glycosylation and reduced effector function |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI655207B (zh) * | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| EP3108255B1 (en) | 2014-02-18 | 2020-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway |
| TW202417497A (zh) * | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| KR102563568B1 (ko) | 2016-11-08 | 2023-08-04 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체에 길항하는 항원-결합 단백질 |
| CN107760761A (zh) | 2017-11-10 | 2018-03-06 | 江苏省农业科学院 | 一种加强瘦素激发lepr信号转导的方法 |
| CA3084385A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
| EP4596043A3 (en) | 2018-04-06 | 2025-10-01 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia |
-
2016
- 2016-10-07 TW TW112125041A patent/TW202417497A/zh unknown
- 2016-10-07 TW TW111100429A patent/TWI824372B/zh active
- 2016-10-07 TW TW105132493A patent/TWI752920B/zh active
- 2016-10-11 EA EA201890928A patent/EA201890928A1/ru unknown
- 2016-10-11 JP JP2018518592A patent/JP7034068B2/ja active Active
- 2016-10-11 HR HRP20220426TT patent/HRP20220426T8/hr unknown
- 2016-10-11 AU AU2016338851A patent/AU2016338851B2/en active Active
- 2016-10-11 PL PL16785072T patent/PL3362477T3/pl unknown
- 2016-10-11 LT LTEPPCT/US2016/056465T patent/LT3362477T/lt unknown
- 2016-10-11 CN CN201680072173.1A patent/CN108368177B/zh active Active
- 2016-10-11 RS RS20220294A patent/RS63061B1/sr unknown
- 2016-10-11 KR KR1020187013185A patent/KR20180070609A/ko not_active Ceased
- 2016-10-11 UY UY0001036942A patent/UY36942A/es not_active Application Discontinuation
- 2016-10-11 IL IL316563A patent/IL316563A/en unknown
- 2016-10-11 SM SM20220125T patent/SMT202200125T1/it unknown
- 2016-10-11 MY MYPI2018701183A patent/MY187975A/en unknown
- 2016-10-11 PT PT167850726T patent/PT3362477T/pt unknown
- 2016-10-11 SI SI201631477T patent/SI3362477T1/sl unknown
- 2016-10-11 KR KR1020257014408A patent/KR20250069979A/ko active Pending
- 2016-10-11 IL IL300961A patent/IL300961B2/en unknown
- 2016-10-11 EP EP16785072.6A patent/EP3362477B1/en active Active
- 2016-10-11 EP EP21207469.4A patent/EP4071173A1/en active Pending
- 2016-10-11 ES ES16785072T patent/ES2908574T3/es active Active
- 2016-10-11 MX MX2018004531A patent/MX2018004531A/es unknown
- 2016-10-11 UA UAA201803447A patent/UA124419C2/uk unknown
- 2016-10-11 BR BR112018007318-0A patent/BR112018007318A2/en active Search and Examination
- 2016-10-11 CA CA3000215A patent/CA3000215A1/en active Pending
- 2016-10-11 SG SG10201913432RA patent/SG10201913432RA/en unknown
- 2016-10-11 DK DK16785072.6T patent/DK3362477T3/da active
- 2016-10-11 WO PCT/US2016/056465 patent/WO2017066204A1/en not_active Ceased
- 2016-10-11 US US15/290,967 patent/US10023644B2/en active Active
- 2016-10-11 HU HUE16785072A patent/HUE058280T2/hu unknown
-
2018
- 2018-03-26 PH PH12018500663A patent/PH12018500663A1/en unknown
- 2018-03-26 ZA ZA2018/01975A patent/ZA201801975B/en unknown
- 2018-03-29 IL IL258448A patent/IL258448B2/en unknown
- 2018-04-11 CO CONC2018/0003852A patent/CO2018003852A2/es unknown
- 2018-04-12 MX MX2023000738A patent/MX2023000738A/es unknown
- 2018-04-12 CL CL2018000946A patent/CL2018000946A1/es unknown
- 2018-06-13 US US16/007,812 patent/US10618968B2/en active Active
- 2018-06-13 US US16/007,848 patent/US10253102B2/en active Active
-
2019
- 2019-05-28 CL CL2019001434A patent/CL2019001434A1/es unknown
- 2019-10-04 US US16/593,761 patent/US20200031946A1/en not_active Abandoned
-
2021
- 2021-03-11 JP JP2021039405A patent/JP7165225B2/ja active Active
- 2021-11-30 US US17/539,034 patent/US12275792B2/en active Active
-
2022
- 2022-03-31 CY CY20221100249T patent/CY1125102T1/el unknown
- 2022-10-21 JP JP2022169008A patent/JP7436603B2/ja active Active
-
2023
- 2023-07-19 AU AU2023206125A patent/AU2023206125A1/en active Pending
- 2023-11-30 JP JP2023202680A patent/JP7699191B2/ja active Active
-
2024
- 2024-02-09 JP JP2024018406A patent/JP7759417B2/ja active Active
- 2024-08-20 US US18/810,454 patent/US20250051465A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535948A5 (cg-RX-API-DMAC7.html) | ||
| CN106068125B (zh) | 治疗脂肪组织积聚的组合物和方法 | |
| CN117024583A (zh) | 抗N3pGlu淀粉状蛋白β肽抗体及其用途 | |
| IL295230A (en) | Combination therapy with anti-cd73 antibodies | |
| JP2011506483A5 (cg-RX-API-DMAC7.html) | ||
| HRP20220426T1 (hr) | Proteini koji vezuju antigen koji aktiviraju receptor leptina | |
| CN102027015A (zh) | 抗cxcr4抗体 | |
| ES3001197T3 (es) | Agente de unión anti-adrenomedulina (ADM) para su uso en la terapia o prevención de síntomas de enfermedad | |
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| US20170319689A1 (en) | Methods, Regimens, Combinations & Antagonists | |
| EP3250597A1 (en) | Vegfa/ang2 compounds | |
| JP2022547452A (ja) | Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療 | |
| CA3169994A1 (en) | Methods for the treatment of scleroderma and related conditions | |
| KR20250084991A (ko) | 항-FcRN 항체를 이용한 만성 염증성 탈수초성 다발성 신경병증의 치료 방법 | |
| EP3145544B1 (en) | Ang2 antibodies | |
| AU2009322587B2 (en) | Anti-ferroportin 1 monoclonal antibodies and uses thereof | |
| KR20250122524A (ko) | 미오스타틴 활성화의 선택적이고 강력한 억제 항체 | |
| CN111886252A (zh) | 促进胰岛细胞生长的方法 | |
| CA2638869A1 (en) | Humanized anti-ghrelin antibodies | |
| TWI454481B (zh) | 結合ＴＧＦ－α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體 | |
| JP2018533588A (ja) | 治療パラダイム | |
| JP2009538916A5 (cg-RX-API-DMAC7.html) | ||
| EP4584294A1 (en) | Methods of treating graves' disease using anti-fcrn antibodies | |
| CN119584995A (zh) | 组合疗法 | |
| JP2010540660A5 (cg-RX-API-DMAC7.html) |